论文部分内容阅读
目的 :探索新辅助化疗治疗对炎性乳腺癌 ( IBC)总生存率及无瘤生存率的影响。方法 :共收治的 18例炎性乳腺癌中 ,7例接受了包括新辅助化疗在内的综合治疗 ( NEO组 ) ,8例接受了常规的综合治疗 ( No—NEO组 ) ,3例只接受化疗或 /和放疗。结果 :NEO组、No—NEO组 6月、1年、2年、3年的总生存率分别为 10 0 % ( 7//7)、10 0 % ( 6/6)、80 .0 % ( 4 /5)、50 % ( 2 /4) 87.5% ( 7/8)、71.4 % ( 5/7)、33.3% ( 2 /6)、16.7% ( 1/6) ;无瘤生存率分别为 10 0 % ( 7/7)、83.3% ( 5/6)、60 .0 % ( 3/5)、50 % ( 2 4 )75.0 % ( 6/8)、4 2 .8% ( 3/7)、2 8.6% ( 2 /7)、0 % ( 0 /6)。结论 :NEO作为综合治疗中的一种治疗方法可能改善 IBC患者的预后。
Objective : To explore the effect of neoadjuvant chemotherapy on the overall survival and tumor-free survival of inflammatory breast cancer ( IBC ). Methods: Of the 18 inflammatory breast cancers that were treated, 7 received comprehensive treatment including neoadjuvant chemotherapy (NEO group), 8 received conventional comprehensive treatment (No-NEO group), and 3 received only Chemotherapy or/and radiation therapy. Results: The overall survival rates of NEO group and No-NEO group at June, 1 year, 2 years, and 3 years were 100% (7//7), 100% (6/6), and 80.0 % ( 4/5), 50% (2/4) 87.5% (7/8), 71.4% (5/7), 33.3% (2/6), 16.7% (1/6); tumor-free survival rates were 10 0 % (7/7), 83.3% ( 5/6), 60. 0 % ( 3/5), 50% (2 4 ) 75.0 % ( 6/8), 4 2 .8% ( 3/7 ), 2 8.6% (2/7), 0 % (0/6). Conclusion: NEO as a treatment in comprehensive treatment may improve the prognosis of patients with IBC.